Last reviewed · How we verify

bee venom — Competitive Intelligence Brief

bee venom (bee venom) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Natural product immunomodulator. Area: Immunology, Rheumatology.

marketed Natural product immunomodulator Immunology, Rheumatology Small molecule Live · refreshed every 30 min

Target snapshot

bee venom (bee venom) — Assistance Publique - Hôpitaux de Paris. Bee venom contains multiple bioactive peptides and enzymes that modulate immune function and reduce inflammation through activation of anti-inflammatory pathways and immune cell regulation.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
bee venom TARGET bee venom Assistance Publique - Hôpitaux de Paris marketed Natural product immunomodulator
Apitox - pure honeybee toxin Apitox - pure honeybee toxin Apimeds, Inc. phase 3 Natural product immunomodulator Phospholipase A2, melittin, multiple immune cell receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Natural product immunomodulator class)

  1. Apimeds, Inc. · 1 drug in this class
  2. Assistance Publique - Hôpitaux de Paris · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). bee venom — Competitive Intelligence Brief. https://druglandscape.com/ci/bee-venom. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: